3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Venous Thromboembolism
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Gonadotropin-Releasing Hormone
3
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
Nutrition Assessment
2
palbociclib
1
beta Carotene
1
Vitamin E
1
Testosterone
1
Standard of Care
1
Social Determinants of Health
1
Simvastatin
1
Rosuvastatin Calcium
1
Rivaroxaban
1
Resistance Training
1
Pravastatin
1
Practice Guidelines as Topic
1
Nutritional Status
1
Lysine Acetyltransferase 5
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
Health Information Exchange
1
Geritol
1
Exercise
1
Atorvastatin
1
Ascorbic Acid
1
Angiotensin-Converting Enzyme Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cardiovascular Diseases
×
Rivaroxaban
×
Genitourinary
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled